Chronic Refractory Cough Market

Market Overview: 

The chronic refractory cough market reached a value of USD 9.8 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 14.7 Billion by 2035, exhibiting a growth rate (CAGR) of 3.81% during 2025-2035.

The chronic refractory cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2025-2035". Chronic refractory cough (CRC) is a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The disease can significantly affect an individual's quality of life, causing sleep disturbances, fatigue, and social isolation. The main symptom of this illness includes a dry, irritated cough localized around the laryngeal area. Other common indications of CRC involve globus, dyspnea, dysphonia, dizziness, persistent chest pain, night sweats, and physical complications, such as urinary incontinence, fractured ribs, muscle strain, etc. The diagnosis of this condition typically requires the identification of a patient's clinical features, medical history, and physical exam. A blood workup and allergy test can be utilized to evaluate signs of infection or other environmental factors that could be causing underlying symptoms. The healthcare provider may also perform spirometry or pulmonary function tests, which help determine lung functionality by measuring airflow in and out of the lungs. Additionally, laryngeal examination using flexible nasendoscopy, that detects the existence of laryngeal lesions or atypical motor patterns contributing to disease symptoms and laryngeal discomfort, is recommended among patients.

The increasing incidences of respiratory tract disorders secondary to sensory nerve damage caused by viral infections, inflammation, allergic factors, etc., are primarily driving the chronic refractory cough market. Besides this, the rising prevalence of various associated risk factors, including smoking, acid reflux, asthma, exposure to irritants, etc., which can irritate the airways, is also bolstering the market growth. Furthermore, the widespread adoption of neuro-modulating agents, like gabapentin and amitriptyline, since they act on the heightened neural sensitization that is linked with the pathogenesis of CRC, is creating a positive outlook for the market. Apart from this, the escalating utilization of non-pharmacological interventions, such as cough-suppression physiotherapy and speech therapy in patients who have failed or not responded to conventional medicinal regimens, is also augmenting the market growth. Additionally, the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life, is further expected to drive the chronic refractory cough market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic refractory cough market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic refractory cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic refractory cough market in any manner.

Key Highlights:

• Refractory chronic cough impacts up to 10 percent of persons worldwide.
• Chronic cough affects approximately 10% of adults across different populations.
• Chronic cough is more prevalent in Europe, America, and Australia (10-20%) compared to Asia (<5%).
• In Copenhagen, Denmark, the total prevalence of chronic cough was 4%, with 3% in never-smokers, 4% in past smokers, and 8% in current smokers.
• The prevalence of persistent cough in children ranges between 1.1% and 21.9%.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic refractory cough market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic refractory cough market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic refractory cough marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic refractory cough market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the chronic refractory cough across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the chronic refractory cough across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2019-2035) of chronic refractory cough across the seven major markets?
• What is the number of prevalent cases (2019-2035) of chronic refractory cough by age across the seven major markets?
• What is the number of prevalent cases (2019-2035) of chronic refractory cough by gender across the seven major markets?
• How many patients are diagnosed (2019-2035) with chronic refractory cough across the seven major markets?
• What is the size of the chronic refractory cough patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic refractory cough?
• What will be the growth rate of patients across the seven major markets?

Chronic Refractory Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic refractory cough drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic refractory cough market?
• What are the key regulatory events related to the chronic refractory cough market?
• What is the structure of clinical trial landscape by status related to the chronic refractory cough market?
• What is the structure of clinical trial landscape by phase related to the chronic refractory cough market?
• What is the structure of clinical trial landscape by route of administration related to the chronic refractory cough market?